Posted by Michael Wonder on 13 Jan 2026
Galderma announces the authorisation of Nemluvio (nemolizumab) for atopic dermatitis and prurigo nodularis in Canada
12 January 2026 - Nemluvio is now authorised for sale by Health Canada based on results from the Phase III ARCADIA and OLYMPIA clinical trial programs, which showed that Nemluvio significantly improved itch, skin lesions and sleep disturbance in atopic dermatitis and prurigo nodularis.
Galderma Canada has announced the Health Canada authorisation of Nemluvio (nemolizumab), a first-in-class biologic treatment for both moderate to severe atopic dermatitis and prurigo nodularis.
